Sequentify
Last updated: May 30, 2026
Israeli biotech startup developing AI-driven DNA sequencing library preparation for rapid, cost-effective genomic testing across oncology, infectious disease, and precision medicine applications.
Visit WebsiteCompany Overview
Sequentify is an Israeli synthetic biology and genomics startup founded in 2021 as a spinoff from the Weizmann Institute of Science. The company specializes in next-generation sequencing (NGS) sample processing, with a primary focus on democratizing genomic testing through its proprietary InfiniSeq™ platform. InfiniSeq significantly streamlines and accelerates the upstream library preparation phase of DNA sequencing workflows—typically reducing preparation time from 8-12 hours to just 3.5 hours while cutting costs, reducing manual labor, and minimizing human error through a four-step automated protocol compatible with high-throughput systems like Bio Molecular Systems Myra®.
At its core, Sequentify combines synthetic biology and artificial intelligence to address a critical bottleneck in modern genomics. As sequencing hardware costs have dropped dramatically over the past decade, library preparation—the process of preparing DNA samples for sequencing—has become the dominant cost and time constraint in many clinical and research laboratories. By developing targeted, highly flexible NGS panels combined with rapid library prep chemistry, Sequentify enables decentralized genomic testing, moving diagnostic infrastructure away from centralized sequencing hubs and into distributed clinical and research labs worldwide.
The company's InfiniSeq protocol incorporates Unique Molecular Identifiers (UMIs) for each sample and probe, enabling precise variant detection at very low variant allele frequencies (VAF) and eliminating PCR duplicate artifacts—critical for sensitive cancer diagnostics, rare disease detection, and pathogen surveillance. The platform's flexibility supports panel designs ranging from focused single-gene assays to comprehensive multi-thousand-target panels in a single reaction, making it adaptable across oncology, carrier screening, infectious disease surveillance, and virology applications. Sequentify has already established partnerships with leading institutions including Stanford University (for hematologic malignancy research) and Bio Molecular Systems for automation integration, validating product-market fit in high-stakes medical settings.
From a dual-use and resilience perspective, Sequentify's technology has strategic relevance in critical infrastructure and public health security. The ability to rapidly and affordably conduct large-scale pathogen surveillance—detecting emerging infectious diseases, monitoring antibiotic resistance, and identifying novel variants—addresses national biosecurity and pandemic preparedness challenges. The Israel Innovation Authority recognized this potential by awarding Sequentify a $1.3 million grant specifically for developing a culture-free, rapid infectious disease sequencing panel, positioning the company at the intersection of precision medicine, public health, and national resilience. Such capabilities are increasingly viewed as dual-use assets: civilian laboratories can rapidly pivot to epidemic monitoring or forensic pathogen identification while maintaining their diagnostic mission.
Sequentify's business model centers on licensing its InfiniSeq chemistry and software (including the AI-driven analysis suite), selling consumables (reagent kits and probes), and providing data analysis services. The company targets clinical oncology labs, academic research institutions, public health agencies, and reference laboratories globally. With a lean team of 9-16 highly specialized scientists and engineers based in Rehovot, the startup has achieved significant traction and revenue growth for its stage, raising $7 million from OurCrowd and receiving Israeli government backing—a rare combination indicating both commercial and strategic institutional confidence in the technology's impact and defensibility.
Dual-Use Assessment
Sequentify's rapid, scalable pathogen sequencing capabilities serve civilian precision medicine and public health, while simultaneously enabling national biosecurity missions: infectious disease surveillance, antibiotic resistance monitoring, emerging pathogen detection, and pandemic preparedness—critical infrastructure functions with explicit defense implications in an era of biological threats and epidemiological uncertainty.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
Sequentify addresses a massive market bottleneck (NGS library prep) with proprietary chemistry and automation that reduces costs and enables decentralized genomic testing. Strong institutional validation (Weizmann spinoff, Stanford partnership, Israel Innovation Authority grants), proven product-market fit, and expanding applications across oncology, public health, and precision medicine position the company for significant scale. Strategic relevance to biosecurity, pandemic preparedness, and critical diagnostic infrastructure attracts both commercial and government backing.
Strategic Value to U.S.-Israel Alliance
Sequentify sits at the critical intersection of precision medicine, public health infrastructure, and biosecurity. In an era of emerging infectious diseases, drug-resistant pathogens, and pandemic risk, the ability to rapidly, affordably, and accessibly conduct large-scale genomic surveillance is increasingly recognized as both a commercial advantage and a strategic national asset. The company's technology directly enables civilian adoption of advanced diagnostic capabilities while simultaneously serving public health and defense objectives in epidemic or biological threat scenarios. Weizmann Institute heritage and Israel Innovation Authority backing underscore institutional recognition of the dual-use value.
Key Technologies
- Targeted DNA library preparation (InfiniSeq™ protocol)
- NGS sample processing automation
- AI-driven bioinformatics analysis
- Unique Molecular Identifier (UMI) chemistry
- Multi-panel flexible sequencing design
- Rapid pathogen detection and classification
Use Cases & Applications
- Cancer genomics and oncology diagnostics
- Carrier screening and genetic disease detection
- Infectious disease surveillance and pathogen monitoring
- Antibiotic resistance tracking and epidemiology
- Viral variant detection and pandemic monitoring
- Clinical microbiology and hospital epidemiology
- Precision medicine and personalized treatment selection
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- Sequentify Official Website Official company site with product details, InfiniSeq platform overview, and contact information.
- Stanford to use Sequentify kits for Hematological Malignancies NGS Sequencing (PR Newswire) Validates commercial partnership with leading U.S. research institution and product validation in oncology.
- Sequentify Awarded Grant by Israel Innovation Authority for Infectious Disease Sequencing Panel (PR Newswire) Confirms Israel Innovation Authority funding ($1.3M) for pandemic preparedness and biosecurity applications.
- Democratizing Genomics: Sequentify Raises $7M (CTech/Calcalist) Covers $7M funding round led by OurCrowd, company mission, and market opportunity in accessible genomics.
- Sequentify - Weizmann Institute Spinoff Company Profile (PitchBook) Professional funding database confirming founding, team size, funding milestones, and active growth status.
- Profile update timestamp Last updated in the Claw & Talon database on May 30, 2026.
Investor Lens
What this entry is
Private startup
Why it may matter
Sequentify may matter as a Health & BioTech entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify traction
- Verify cap table/funding
- Verify technical claims
- Verify regulatory/export-control issues
- Verify customer concentration
Main investor questions
- Is the company currently active, independently financeable, and raising or not raising on terms you can verify?
- What customer, revenue, product, and technical evidence supports the company story?
- What valuation, cap table, rights, and follow-on assumptions would govern any private exposure?
- Does the dual-use claim map to actual commercial and government/defense/resilience buyer evidence?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies Sequentify's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Where does the product create real defense, intelligence, critical-infrastructure, or emergency-response value beyond ordinary commercial adoption?
- What regulatory, procurement, and buyer-adoption constraints could slow deployment in strategic or government-adjacent markets?
- What would disconfirm the priority signal: weak customer references, thin technical differentiation, poor capital efficiency, or limited allied-market access?
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.